CHICAGO – May 2, 2019 – Today, at the CPhI Conference, Meroven LLC announced a five-year agreement with CURE Pharmaceutical Corporation (OTCQB: CURR) to exclusively market and distribute Spee-D®, a weekly dose oral thin film Vitamin D3 in the USA.
Under the terms of the agreement, Meroven LLC will be responsible for conducting all regulatory activities to obtain marketing authorizations for Spee-D as well as marketing and distribution. CURE will be responsible for the manufacture of Spee-D and its supply to Meroven at a predetermined transfer price.
“This agreement will broaden the reach of our high dose Vitamin D3 CUREfilmTM across the USA,” said Jessica Rousset, Chief Operating Officer of CURE Pharmaceutical. “As we continue to grow our product pipeline, we look forward to continued and expanded opportunities to work with Meroven.”
“CURE Pharmaceutical has cultivated an exceptional reputation in terms of their efficiency and purity of its internal formulation and manufacturing processes,” said Mohammed Alaa, Director of Meroven LLC. “We look forward to a long and fruitful relationship with CURE and anticipate its potential expansion.”
For more information, please visit Booth No. 852 at the CPhI North America Conference May 1-2, 2019 where both Meroven LLC and CURE Pharmaceutical representatives will be available.
About Spee-D® (vitamin D3) oral thin film
Spee-D is an oral thin film that delivers vitamin D3 formulated with CURE’s proprietary CUREfilmTM technology that ensures high potency and stability. Vitamin D is a fat-soluble vitamin that is naturally present in very few foods, added to others, and available as a dietary supplement. It is also produced endogenously when ultraviolet rays from sunlight strike the skin and trigger vitamin D synthesis. Vitamin D promotes calcium absorption and is essential for bone growth. Vitamin D also prevents rickets in children and osteomalacia in adults. Together with calcium, vitamin D also helps protect older adults from osteoporosis.
About CURE Pharmaceutical
CURE Pharmaceutical is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has a full-service cGMP manufacturing facility and is a pioneering developer and manufacturer of a patented and proprietary delivery system (CUREfilm™), one of the most advanced oral thin film on the market today. CURE is developing an array of products in innovative delivery platforms and partners with biotech and pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada and Israel. The company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced.
CURE Pharmaceutical is traded under the symbol CURR. For more information about CURE Pharmaceutical, please visit its website at www.curepharmaceutical.com.
About Meroven LLC
Meroven LLC is a Florida-based Pharmaceutical company that manufactures and trades in medical, pharmaceutical, OTC and other healthcare products. Meroven’s scope of business includes manufacturing pharmaceutical and healthcare products and trading in medical devices, durable medical goods and consumables.
Meroven LLC has established strategic international partnerships with other leading companies in healthcare to support its vision. These partnerships span from USA, Canada, and the EU. Meroven offers its clients quality generic medicines that fill a niche, gap and/or offer innovative technologies for delivery.
This press release contains forward-looking statements and forward-looking information, or, collectively, forward-looking statements, within the meaning of applicable securities laws, that are based on our management’s belief and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as “may”, “will”, “should”, “could”, “would”, “outlook”, “believe”, “plan”, “envisage”, “anticipate”, “expect” and “estimate” or the negatives of these terms, or variations of them. The forward-looking statements contained in this press release include, but are not limited to, the efficacy of Spee-D® and its use.
CURE Media Contact:
Olmstead Williams Communications